20.96
+0.6(+2.95%)
Currency In USD
| Previous Close | 20.36 |
| Open | 20.61 |
| Day High | 20.96 |
| Day Low | 20.43 |
| 52-Week High | 27.64 |
| 52-Week Low | 18.8 |
| Volume | 269,886 |
| Average Volume | 883,109 |
| Market Cap | 901.73M |
| PE | 45.57 |
| EPS | 0.46 |
| Moving Average 50 Days | 23.53 |
| Moving Average 200 Days | 24.17 |
| Change | 0.6 |
If you invested $1000 in Pacira BioSciences, Inc. (PCRX) 10 years ago, it would be worth $360.01 as of February 06, 2026 at a share price of $20.96. Whereas If you bought $1000 worth of Pacira BioSciences, Inc. (PCRX) shares 5 years ago, it would be worth $276.59 as of February 06, 2026 at a share price of $20.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
GlobeNewswire Inc.
Jan 28, 2026 1:00 PM GMT
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovativ
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
GlobeNewswire Inc.
Jan 13, 2026 1:00 PM GMT
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), th
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
GlobeNewswire Inc.
Jan 08, 2026 9:01 PM GMT
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its